{"contacts": [{"terms": [{"accession": "MS:1000586", "name": "contact name", "value": "Srikanth Rapole"}, {"accession": "MS:1000589", "name": "contact email", "value": "nccsproteomics@gmail.com"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "NCCS, Pune"}, {"accession": "MS:1002037", "name": "dataset submitter"}]}, {"terms": [{"accession": "MS:1002332", "name": "lab head"}, {"accession": "MS:1000586", "name": "contact name", "value": "Srikanth Rapole"}, {"accession": "MS:1000589", "name": "contact email", "value": "rsrikanth@nccs.res.in"}, {"accession": "MS:1000590", "name": "contact affiliation", "value": "Proteomics Lab, National Centre for Cell Science (NCCS), Pune-411007, Maharashtra, India."}]}], "datasetFiles": [{"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859/Rslts_MM_BTZ_ITRAQ.xlsx"}, {"accession": "MS:1002849", "name": "Search engine output file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859/Rslts_MM_BTZ_LFQ.xlsx"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859/MM_RPMI_DR_ITRAQ_01.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859/MM_RPMI_DR_ITRAQ_02.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859/MM_RPMI_DR_ITRAQ_03.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859/MM_RPMI_DR_ITRAQ_04.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859/MM_RPMI_DR_ITRAQ_05.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859/MM_RPMI_DR_ITRAQ_06.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859/MM_RPMI_DR_ITRAQ_07.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859/MM_RPMI_DR_ITRAQ_08.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859/MM_RPMI_DR_ITRAQ_09.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859/MM_RPMI_DR_ITRAQ_10.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859/RPMI_Resistance_01.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859/RPMI_Resistance_02.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859/RPMI_Resistance_03.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859/RPMI_Sensitive_01.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859/RPMI_Sensitive_02.raw"}, {"accession": "MS:1002846", "name": "Associated raw file URI", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859/RPMI_Sensitive_03.raw"}], "description": "Among the blood cancers, 13% mortality is caused by Multiple myeloma (MM) type of haematological malignancy. In spite of therapeutic advances in chemotherapy treatment, still MM remains an incurable disease is mainly due to emergence of chemoresistance. At present time, FDA approved bortezomib is the first line drug for MM treatment. However, like other chemotherapy, MM patients are acquiring resistance against bortezomib. The present study aims to identify and validate bortezomib resistant protein targets in MM using iTRAQ and label free quantitative proteomic approaches. 125 differentially expressed proteins were commonly found in both approaches with similar differential expression pattern. XPO1 protein was selected for further validation as its significant high expression was observed in both iTRAQ and label free analysis. Bioinformatic analysis of these common differentially expressed proteins showed a clear cluster of proteins such as SMC1A, RCC2, CSE1, NUP88, NUP50, TPR, HSPA14, DYNLL1, RAD21 and RANBP2 being associated with XPO1.  Functional studies like cell count assay, flow cytometry assay and soft agar assay proved that XPO1 knock down in RPMI 8226R cell line results in re-sensitization to bortezomib drug", "fullDatasetLinks": [{"accession": "MS:1002852", "name": "Dataset FTP location", "value": "ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2019/09/PXD013859"}, {"accession": "MS:1001930", "name": "PRIDE project URI", "value": "http://www.ebi.ac.uk/pride/archive/projects/PXD013859"}], "identifiers": [{"accession": "MS:1001919", "name": "ProteomeXchange accession number", "value": "PXD013859"}], "instruments": [{"accession": "MS:1002416", "name": "Orbitrap Fusion"}], "keywords": [{"accession": "MS:1001925", "name": "submitter keyword", "value": "Multiple myeloma, Chemoresistance, iTRAQ, Label free analysis, XPO1, Bortezomib"}], "modifications": [{"accession": "MOD:01499", "name": "iTRAQ4plex-116 reporter+balance reagent acylated residue"}, {"accession": "MOD:00425", "name": "monohydroxylated residue"}, {"accession": "MOD:00397", "name": "iodoacetamide derivatized residue"}], "publications": [{"terms": [{"accession": "MS:1000879", "name": "PubMed identifier", "value": "31465861"}, {"accession": "MS:1002866", "name": "Reference", "value": "Chanukuppa V, Paul D, Taunk K, Chatterjee T, Sharma S, Kumar S, Santra MK, Rapole S. XPO1 is a critical player for bortezomib resistance in multiple myeloma: A quantitative proteomic approach. J Proteomics. 2019 209:103504"}]}], "species": [{"terms": [{"accession": "MS:1001469", "name": "taxonomy: scientific name", "value": "Homo sapiens (Human)"}, {"accession": "MS:1001467", "name": "taxonomy: NCBI TaxID", "value": "9606"}]}], "title": "XPO1 is a critical player for Bortezomib resistance in Multiple Myeloma: A quantitative proteomic approach"}